Spectrum Pharmaceuticals is a commercial-stage biotechnology company with fully integrated commercial and drug development operation. The Company and its subsidiaries have six marketed oncology/hematology products, three for different types of non-Hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia and one for multiple myeloma. There are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.

Type
Public
HQ
Henderson, US
Founded
2002
Size (employees)
227 (est)
Website
sppirx.com
Spectrum Pharmaceuticals was founded in 2002 and is headquartered in Henderson, US
Report incorrect company information

Spectrum Pharmaceuticals Office Locations

Spectrum Pharmaceuticals has an office in Henderson
Henderson, US (HQ)
240 11500 S Eastern Ave
Show all (1)
Report incorrect company information

Spectrum Pharmaceuticals Financials and Metrics

Spectrum Pharmaceuticals Financials

Spectrum Pharmaceuticals's revenue was reported to be $128.37 m in FY, 2017
USD

Revenue (FY, 2017)

128.4 m

Gross profit (FY, 2017)

85.5 m

Gross profit margin (FY, 2017), %

66.6%

Net income (FY, 2017)

(91.2 m)

EBIT (FY, 2017)

(96.7 m)

Market capitalization (23-Apr-2018)

1.6 b

Cash (31-Dec-2017)

227.3 m
Spectrum Pharmaceuticals's current market capitalization is $1.6 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

143.5 m186.5 m136.9 m146.4 m128.4 m

Revenue growth, %

30%(27%)7%

Cost of goods sold

28.6 m27 m27.7 m28 m42.9 m

Gross profit

114.9 m159.5 m109.2 m118.5 m85.5 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

42.4 m40.1 m46.9 m48 m38.6 m45 m28.6 m43.9 m33.9 m33.4 m29.1 m34.3 m

Cost of goods sold

8.2 m6.3 m6.2 m6.5 m7.1 m6 m8.4 m5.6 m5.6 m7.5 m8.1 m11.3 m

Gross profit

34.2 m33.8 m40.7 m41.5 m31.5 m39 m20.2 m38.3 m28.3 m25.9 m21 m23 m

Gross profit Margin, %

81%84%87%86%82%87%70%87%83%78%72%67%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

156.3 m129.9 m139.7 m158.2 m227.3 m

Accounts Receivable

7.5 m5.5 m12.6 m5.8 m

Inventories

13.5 m9.2 m4.2 m8.7 m5.7 m

Current Assets

235.2 m222.5 m191.3 m216.7 m277.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

72 m117.7 m132.4 m144.2 m123.4 m142.3 m136.5 m132.3 m155.8 m171.6 m137.2 m138.3 m

Accounts Receivable

8.2 m11.8 m9.3 m7.9 m8.2 m13.5 m15.2 m7 m7.1 m5.9 m4 m

Inventories

14.6 m12.9 m10.9 m9.9 m9.1 m8.8 m7.1 m3.2 m6.4 m7.3 m10.4 m10.2 m

Current Assets

153.5 m215.7 m220.1 m231.6 m216 m207.2 m209.5 m172.5 m206.7 m231.4 m197 m199 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(62.1 m)(45.7 m)(50.8 m)(68.5 m)(91.2 m)

Depreciation and Amortization

22.1 m25.4 m31.9 m26.5 m28 m

Inventories

1.6 m4.3 m1.9 m(5.8 m)4.3 m

Accounts Payable

Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(7.8 m)(27.6 m)(3.6 m)(11.5 m)(25.6 m)(2.3 m)(18.7 m)(9.3 m)(24.3 m)(17.5 m)(23 m)(43.4 m)

Depreciation and Amortization

7 m14 m

Inventories

10.9 m9.9 m9.1 m8.8 m7.1 m3.2 m6.4 m7.3 m(1.2 m)428 k

Cash From Operating Activities

(20.1 m)(19.5 m)
USDY, 2017

Revenue/Employee

578.2 k

Financial Leverage

1.4 x
Show all financial metrics

Spectrum Pharmaceuticals Operating Metrics

FY, 2016

Phase I Trials Products

3

Phase II Trials Products

1

Phase III Trials Products

3
Show all operating metrics
Report incorrect company information